检索结果-南通市图书馆

Treatment of inflammatory bowel disease:A review of medical therapy

World Journal of Gastroenterology 2008年第3期14卷 354-377页

作者： Patricia L Kozuch stephen b hanauer Division of Gastroenterology and Hepatology Department of Medicine Thomas Jefferson University Hospital Philadelphia PA United States University of Chicago Hospitals Department of Medicine Section of Gastroenterology and Nutrition Chicago IL 60637 United States

Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract. While a cure remains elusive, both can be treated with medications that induce and maintain remission. With the recent advent of therapies that inhibit tumor necrosis factor (TNF) alpha the overlap in medical therapies for UC and CD has become greater. Although 5-ASA agents have been a mainstay in the treatment of both CD and UC, the data for their efficacy in patients with CD, particularly as maintenance therapy, are equivocal. Antibiotics may have a limited role in the treatment of colonic CD. Steroids continue to be the first choice to treat active disease not responsive to other more conservative therapy; non- systemic steroids such as oral and rectal budesonide for ileal and right-sided CD and distal UC respectively are also effective in mild-moderate disease. 6-mercaptopurine (6-MP) and its prodrug azathioprine are steroid-sparing immunomodulators effective in the maintenance of remission of both CD and UC, while methotrexate may be used in both induction and maintenance of CD. Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC.

关键词： Inflammatory bowel disease Crohn's disease Ulcerative colitis Medical therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

One man’s trash-another man’s treasure: fecal transplantation

引用

Hepatobiliary Surgery and Nutrition 2019年第6期8卷 623-625页

作者： Nancy Gupta stephen b.hanauer Digestive Health Center University of Iowa Hospitals and ClinicsIowa CityIAUSA Digestive Health Center Northwestern University Feinberg School of MedicineChicagoILUSA

Discovery of immune checkpoint inhibitors has revolutionized the field of *** checkpoints play a key role in maintaining immune homeostasis and preventing *** normal situation,immune responses are regulated by a balance between co-stimulatory and inhibitory signals referred to as"immune checkpoints".Activated T cells express multiple co-inhibitory receptors such as lymphocyte-activation gene 3(LAG-3),programmed cell death protein 1(PD-1)and cytotoxic T-lymphocyte-associated protein 4(CTLA-4)that are primary mediators of immune effector responses to self-proteins,chronic infections and tumor *** tumors these immune checkpoints allow the tumor cells to dodge anti-tumor response(1).Checkpoint inhibitors(CPI)block these immune checkpoints allowing the immune system to attack tumor cells(2).Although the immune system has the inherent ability to distinguish self from non-self and thus typically mount an attack on the non-self-cancer cells;over-activation of the immune response can lead to serious adverse events collectively called immune-related adverse events(irAEs)(3).While activation of the immune system and development of irAEs has been associated with better outcomes for underlying cancer(4),the associated side effects increase morbidity and mortality in addition to having a negative impact on patient’s quality of *** associated with CPI therapy can have delayed manifestation and present after the CPI have been discontinued(5).

关键词： homeostasis mortality collective

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

溃疡性结肠炎

引用

英国医学杂志中文版 2017年第7期20卷 387-392页

作者： Alexander C Ford Paul Moayyedl Steven b hanauer Joseph b Kirsner 谭蓓吴东 Leeds Gastroenterology Institute St James's University Hospital Leeds LS9 7TF UK Leeds Institute of Molecular Medicine Leeds University Leeds UK McMaster University Medical Centre Hamilton ON Canada University of Chicago 5481 S Maryland Ave Chicago IL USA 北京协和医院消化科

溃疡性结肠炎（ulcerativecolitis，uc）是一种消化道炎症性疾病，病变主要位于结直肠。UC好发于青年人，发达国家的人群患病率较高。UC表现为结直肠弥漫性、连续性浅表炎症，以及相应的组织学改变。下消化道内镜或影像检查可以明确诊... 详细信息

溃疡性结肠炎（ulcerativecolitis，uc）是一种消化道炎症性疾病，病变主要位于结直肠。UC好发于青年人，发达国家的人群患病率较高。UC表现为结直肠弥漫性、连续性浅表炎症，以及相应的组织学改变。下消化道内镜或影像检查可以明确诊断。目前尚未发现UC的明确病因，其发病机制与遗传易感个体的结肠内环境变化有关，具有慢性、终身、易复发的病程特点。

关键词：溃疡性结肠炎治疗方法消化系统医疗卫生行业

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

人抗肿瘤坏死因子单克隆抗体(阿达木单抗)在克罗恩病中的研究:标准一级试验

引用

世界核心医学期刊文摘（胃肠病学分册） 2006年第8期2卷 23-24页

作者： hanauer S. b. Sandborn W. J. Rutgeerts P. 赵天智(译) 张欣(校) Division of Gastroenterology University of Chicago Medical Center 5841 South Maryland Avenue Chicago IL 60637 United States 不详

background& Aims: Tumor necrosis factor blockade has been shown to be an effective treatment strategy in Crohn’s disease (CD). Adalimumab is a human immunoglobulin G1 (IgG1)- monoclonal antibody targeting tumor necrosis factor (TNF). A randomized, double-blind, placebo-contro-lled, dose-ranging trial was performed to evaluate the efficacy of adalimumab induction therapy in patients with CD. Methods: A total of 299 patients with moderate to severe CD naive to anti-TNF therapy were randomized to receive subcutaneous injections at weeks 0 and 2 with adalimumab 40 mg/20 mg, 80 mg/40 mg, or 160 mg/80 mg or placebo. The primary endpoint was demonstration of a significant difference in the rates of remission at week 4 (defined as a Crohn’s Disease Activity Index score bo groups. Results: The rates of remission at week 4 in the adalimumab 40 mg/20 mg, 80 mg/40 mg, and 160 mg/80 mg groups were 18% (P = .36), 24% (P = .06), and 36% (P = .001), respectively, and 12% in the placebo group. Adverse events occurred at similar frequencies in all 4 treatment groups except injection site reactions, which were more common in adalimumab-treated patients. Conclusions: Adalimumab was superior to placebo for induction of remission in patients with moderate to severe Crohn’s disease naive to anti-TNF therapy. The optimal induction dosing regimen for adalimumab in this study was 160 mg at week 0 followed by 80 mg at week 2. Adalimumab was well tolerated.

关键词：抗肿瘤坏死因子单克隆抗体阿达木单抗克罗恩病肿瘤坏死因子(TNF) 试验安慰剂对照抗-TNF治疗标准人免疫球蛋白阻断治疗

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：